The Challenge
Stop MASLD!
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major chronic disease. There is a high medical need for MASLD/MASH treatment, as the prevalence continues to rise. This disease is associated with severe injury of hepatocytes leading to fibrosis and liver cirrhosis. CureDiab addresses MASH with a novel first-in-class therapy.
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a major chronic disease. There is a high medical need for MASLD/MASH treatment, as the prevalence continues to rise. This disease is associated with severe injury of hepatocytes leading to fibrosis and liver cirrhosis. CureDiab addresses MASH with a novel first-in-class therapy.
Fatty liver - a global disease
MASLD is worldwide the most common chronic liver disease affecting 25% of worldwide population. Not only adults are affected, even every 3rd child with obesity develops MASLD.
The advanced MASH form is a severe liver disease with a prevalence estimated between 1.5-6.5% of the population and is the leading cause for liver cirrhosis, transplantation, and liver carcinoma. At least 50% of the MASH patients develop type 2 diabetes.
More than 160 million MASLD patients and more than 27 million MASH patients are affected in Europe and USA. Worldwide more than 1.5 billion patients suffer from MASLD and 225 million from MASH. The yearly growth for MASLD patients is strong (2.2%) and even higher for MASH patients (6.3%).
The advanced MASH form is a severe liver disease with a prevalence estimated between 1.5-6.5% of the population and is the leading cause for liver cirrhosis, transplantation, and liver carcinoma. At least 50% of the MASH patients develop type 2 diabetes.
More than 160 million MASLD patients and more than 27 million MASH patients are affected in Europe and USA. Worldwide more than 1.5 billion patients suffer from MASLD and 225 million from MASH. The yearly growth for MASLD patients is strong (2.2%) and even higher for MASH patients (6.3%).
Next to the high medical need MASLD creates a high financial pressure on the health systems. In Europe and USA MASLD annual direct medical costs are about 126 billion Euros / year. Therefore, there is a high medical need to develop a pharmacotherapy. MASLD/MASH are left with very few management options. Very recently resmetirom has been approved as the only pharmacological intervention for MASH.
Therapeutic approaches that integrate multiple combined treatments, targeting diverse metabolic risk factors simultaneously, hold greater promise for enhancing MASH and its associated comorbidities. It is expected that in the future, a precision medicine-oriented combination therapy strategy will be employed to address the progressive stages of MASLD.
Therapeutic approaches that integrate multiple combined treatments, targeting diverse metabolic risk factors simultaneously, hold greater promise for enhancing MASH and its associated comorbidities. It is expected that in the future, a precision medicine-oriented combination therapy strategy will be employed to address the progressive stages of MASLD.
Our modern laboratory
© 2022 cureDiab All rights reserved